Venus Medtech (Hangzhou) (SEHK:2500) - Hisse Senedi Fiyatı, Haberler ve Analizler

2500 Stoklara Genel Bakış

Engages in the research, development, clinical development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. Daha fazla detay

2500 temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 23.4% daha düşük bir oranda işlem görüyor

Gelirin yılda 31.93% oranında artması öngörülüyor

Risk Analizi

Hisse senetleri oldukça likit değildir

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Venus Medtech (Hangzhou) Inc. Rakipler

Acotec Scientific Holdings

SEHK:6669

HK$2.3b

Sisram Medical

SEHK:1696

HK$1.6b

Modern Dental Group

SEHK:3600

HK$3.4b

MicroPort CardioFlow Medtech

SEHK:2160

HK$1.7b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Venus Medtech (Hangzhou)
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$5.62
52 Haftanın En Yüksek Seviyesi	HK$14.94
52 Haftanın En Düşük Seviyesi	HK$3.74
Beta	0.55
11 Aylık Değişim	0%
3 Aylık Değişim	-0.71%
1 Yıllık Değişim	-61.61%
33 Yıllık Değişim	-92.66%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-86.95%

Son Haberler & Güncellemeler

Recent updates

Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Apr 07

Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

Oct 12

Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

Sep 04

We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

Jul 28

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Mar 29

Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Jan 09

Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

Dec 01

We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

Aug 16

A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

Jul 12

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Apr 26

Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

Apr 05

Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate

Mar 07

What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?

Feb 14

Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner

Jan 19

Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?

Dec 29

Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?

Dec 29

Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?

Dec 08

Hissedar Getirileri

	2500	HK Medical Equipment	HK Pazar
7D	0%	-0.8%	1.6%
1Y	-61.6%	-38.3%	10.1%

Getiri vs. Endüstri: 2500 geçen yıl % -38.3 oranında getiri sağlayan Hong Kong Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: 2500 geçen yıl % 10.1 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 2500's price volatile compared to industry and market?
2500 volatility
2500 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	9.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.3%

İstikrarlı Hisse Senedi Fiyatı: 2500 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 2500 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	1,006	Lin Haosheng Lim	www.venusmedtech.com

Venus Medtech (Hangzhou) Inc. Temel Bilgiler Özeti

Venus Medtech (Hangzhou)'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
2500 temel i̇stati̇sti̇kler
Piyasa değeri	HK$2.46b
Kazançlar(TTM)	-HK$1.31b
Gelir(TTM)	HK$491.35m

5.0x

P/S Oranı

-1.9x

F/K Oranı

2500 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
2500 gelir tablosu (TTM)
Gelir	CN¥452.11m
Gelir Maliyeti	CN¥101.03m
Brüt Kâr	CN¥351.07m
Diğer Giderler	CN¥1.56b
Kazançlar	-CN¥1.21b

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.76
Brüt Marj	77.65%
Net Kâr Marjı	-267.18%
Borç/Özkaynak Oranı	23.4%

2500 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

2500 Stoklara Genel Bakış

Ödüller

Risk Analizi

Venus Medtech (Hangzhou) Inc. Rakipler

SEHK:6669

HK$2.3b

SEHK:1696

HK$1.6b

SEHK:3600

HK$3.4b

SEHK:2160

HK$1.7b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Recent updates

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

New minor risk - Share price stability

Venus Medtech (Hangzhou) Inc. Announces Executive Changes

Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?

No longer forecast to breakeven

Venus Medtech (Hangzhou) Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023

Consensus EPS estimates fall by 24%

No longer forecast to breakeven

First half 2023 earnings released: CN¥0.80 loss per share (vs CN¥0.46 loss in 1H 2022)

Venus Medtech (Hangzhou) Inc. to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Share price stability

Founder recently bought HK$1.9m worth of stock

Venus Medtech (Hangzhou) Inc., Annual General Meeting, Jun 30, 2023

Venus Medtech (Hangzhou) Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary

Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?

Forecast to breakeven in 2025

What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You

Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Consensus revenue estimates fall by 16%

Forecast to breakeven in 2025

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Board Changes

Insider recently sold HK$5.7m worth of stock

Venus Medtech (Hangzhou) Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman

Less than half of directors are independent

Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 20%

Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

Venus Medtech (Hangzhou) Inc. to Report First Half, 2022 Results on Aug 31, 2022

We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System

Venus Medtech (Hangzhou) Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application

Consensus revenue estimates fall by 25%

No longer forecast to breakeven

Venus Medtech (Hangzhou) Inc., Annual General Meeting, May 30, 2022

Forecast breakeven date pushed back to 2023

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2021 Results on Mar 31, 2022

Venus Medtech (Hangzhou) Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation Center

Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Venus Medtech (Hangzhou) Inc. Announces Completion of Global First Clinical Application of Venus-Powerx

Venus Medtech (Hangzhou) Inc. Announces Venus Vitae, Balloon-Expandable Dry Tissue Tavr System Successfully Completed the First Two Implantations in the Fim Clinical Trial

Venus Medtech (Hangzhou) Inc. (SEHK:2500) commences an Equity Buyback Plan for 43,170,744 shares, representing 9.79% of its issued share capital, under the authorization approved on May 21, 2021.

Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

National Medical Products Administration of China Approves Venus Medtech's VenusA-Plus Transcatheter Prosthetic Aortic Valve Replacement System - Retrievable Delivery System